A Form 144 notice of proposed securities sale was filed on November 9, 2026, disclosing that CME Group Inc. director Daniel G. Kaye intends to sell 532 shares of CME Group common stock through Fidelity Brokerage Services LLC.

Key Highlights

  • Seller: Daniel G. Kaye, identified in the filing as a director of CME Group Inc.
  • Shares proposed for sale: 532 shares of CME Group common stock, with an aggregate market value of $163,324.00 according to the filing.
  • Approximate sale date: November 9, 2026, through Fidelity Brokerage Services LLC, 245 Summer Street, Boston, MA 02110.
  • Shares outstanding: The filing reports 357,930,746 shares of common stock outstanding.
  • Original acquisition: The 532 shares were acquired on June 25, 2025, as a stock award from the issuer, with compensation listed as the nature of payment.
  • Prior sales: The filing reports nothing to disclose under sales of issuer securities during the past three months.

CME Group Director Daniel G. Kaye Files Notice to Sell Award Shares

According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission on November 9, 2026, Daniel G. Kaye, a director of CME Group Inc. (NASDAQ:CME), has provided notice of a proposed sale of 532 shares of the company's common stock. The filing lists the aggregate market value of the shares to be sold as $163,324.00. The named broker for the transaction is Fidelity Brokerage Services LLC, located at 245 Summer Street, Boston, MA 02110.

The filing discloses that the 532 shares were originally acquired on June 25, 2025, through a stock award from CME Group Inc., with the nature of payment described as compensation. The filing reports no sales by Kaye of CME Group securities during the three months preceding this notice. The total number of shares of common stock outstanding is listed in the filing as 357,930,746.

The notice was signed by Jordyn Davis as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Daniel G. Kaye. The filing states that the seller represents that he does not know any material adverse information regarding the current and prospective operations of CME Group Inc. that has not been publicly disclosed.

What Was Disclosed

CME Group director Daniel G. Kaye filed a Form 144 on November 9, 2026, disclosing a proposed sale of 532 shares of common stock, originally received as a stock award on June 25, 2025, with an aggregate market value of $163,324.00.